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ABSTRACT
THE REGULATION OF MITOCHONDRIAL UNCOUPLING PROTEINS IN THE HEART,
Karl R. Laskowski, Maria Volkova, and Raymond R. Russell. Section of Cardiovascular
Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven,
CT. The mitochondrial uncoupling proteins (UCPs) are a recently discovered group of proteins
that are present in the inner mitochondrial membrane and mediate a variety of important
functions. Involved in transmembrane proton transport, UCPs regulate cellular metabolism as
well as prevent reactive oxygen species formation (ROS) and detoxify exogenous ROS. In the
heart, these proteins may protect tissue during times of ischemic or metabolic stress. Also
activated during metabolic stress is AMP-activated protein kinase (AMPK), which has been
shown to provide cardioprotection during ischemia/reperfusion. We hypothesized that AMPK
activation plays a role in upregulating the expression of uncoupling proteins UCP2 and UCP3 in
the heart. Using both tissue and cellular models, we demonstrate that pharmacologic activation of
AMPK with the AMP-analogue, AICAR, leads to increases in UCP2 and UCP3 mRNA and
protein expression at both one-hour and twenty-four hour incubation time points. Furthermore,
we identify a segment of the UCP3 promoter that can mediate AMPK-activated transcription. We
conclude that AMPK activation appears to induce increased UCP expression, and that such an
effect is mediated through an interaction with a specific portion of the UCP3 promoter. These
findings support the idea that some degree of the cardioprotective effects observed with AMPK
activation may be due to increased UCP expression in the heart.
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5
INTRODUCTION

Uncoupling Proteins
Structure and Function
The mitochondrial uncoupling proteins, or UCPs, are a group of recently
discovered proteins found in the inner mitochondrial membrane in various mammalian
tissues. Uncoupling proteins are members of the superfamily of anion carrier proteins that
regulate the mitochondrial membrane potential. This membrane potential is created by
the transfer of protons (generated by citric acid cycle flux) from the mitochondrial matrix
to the space between the inner and outer mitochondrial membranes via the
oxidation/reduction reactions of the electron transport chain.

Figure 1. Uncoupling protein function. TCA cycle metabolism of NADH and FADH2 generate a proton
gradient that is utilized by ATP-synthase to create high-energy phosphates (ATP) or is “wasted” through
uncoupling proteins that provide an alternate path for protons to cross the inner mitochondrial membrane.
Adapted from Brownlee, M. Biochemistry and molecular cell biology of diabetic complications, Nature
2001; 414: 813-820.

The proton gradient drives mitochondrial ATP synthesis by F0F1-ATPase, which,
in turn, dissipates the mitochondrial membrane potential. Under steady-state conditions,
this membrane potential is determined by balance between the efflux of protons through
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the electron transport chain and influx through the F0F1-ATPase. Like F0F1-ATPase,
UCPs cause dissipation of the mitochondrial membrane potential through transport of
protons from the space between the inner and outer mitochondrial membranes back into
the mitochondrial matrix. However, in contrast to F0F1-ATPase, no ATP is synthesized
by proton conductance through the UCPs and thus, they act as uncouplers of oxidative
phosphorylation.
The first described uncoupling protein, UCP1 or thermogenin, was found to
dissipate the proton gradient in an “energy wasting” manner, creating heat instead of the
high-energy phosphate, ATP.1 Largely restricted to brown adipose tissue, UCP1 is
responsible for nonshivering thermogenesis. Subsequently, several proteins similar to
UCP1 were identified based on sequence homology, establishing a family of UCPs.
UCP2 was the first structural homolog of UCP1 to be described.2, 3 UCP2 appears to be
present in a variety of tissues throughout the body, although the presence of UCP2
protein in heart is the issue of some controversy and may be species-dependent.4, 5
Like UCP2, uncoupling protein 3 (UCP3) is an inner mitochondrial membrane
protein with significant structural homology to UCP1. However, UCP3 appears to be
present in the heart muscle of mice, rats, and humans.
While the expression of UCP3 in the heart is fairly well established, there remains
conflicting data regarding the relative expression of UCP2 and UCP3 both between
tissues and between species. There may also be substantial differences in the proteins’
function depending on where they are located.2, 6, 7 This variation has greatly complicated
the study of the UCPs and much remains to be elucidated concerning the function of the
UCPs. For example, while the primary function of UCP1 is widely agreed to be heat
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generation in brown fat, the physiologic roles of UCPs 2 and 3 are less certain and remain
the subject of ongoing experimentation and debate.1, 8 Supporting the idea of different
functions is data demonstrating that UCP1 is upregulated by exposure to cold
temperatures and is critical for tolerance to cold, while UCP2 and UCP3 expression are
not effected by cold, but are upregulated in response to fasting.9, 10
Multiple studies have suggested that these UCP2 and UCP3 may function in
regulating metabolism: specifically, in the regulation of fatty acid oxidation or ATP
production.11 Some authors have hypothesized that the UCPs act as pores through which
fatty acids can enter the mitochondria and undergo oxidation.12, 13 While other previous
studies have demonstrated that UCP3 knockout mice have lower rates of whole body
fatty acid oxidation.14 Furthermore, overexpression of UCP2 or UCP3 in cultured muscle
or insulinoma cells increases the rate of fatty acid oxidation and decreases the rate of
glucose oxidation when fatty acids are present.15, 16 Yet metabolic effects may not be the
primary function of the UCPs.
Given the similar structures of the mitochondrial uncoupling proteins and the
known function of UCP1, it is not surprising that UCPs 2 and 3 also appear mediate some
degree of proton leak within the mitochondria.17 However, as mentioned above, UCP2
and UCP3 do not appear to be involved in significant thermogenesis. Although UCP2
and UCP3 are expressed in brown fat, previous research in UCP1-deficient adipocytes
demonstrated that thermogenesis was almost entirely dependent on the presence of
functional UCP1 proteins.18 It has been proposed that the major function of UCP2 and
UCP3 is related to the dissipation of the mitochondrial proton gradient, albeit not to
produce heat. This function has important implications with respect to cellular protection.
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Specifically, by reducing the electrical potential across the inner membrane, the UCPs
reduce production of superoxide radicals at complex I of the mitochondrial respiratory
chain.19 Supporting this hypothesis are observations from isolated skeletal mitochondria
harvested from mice: reactive oxygen species production is significantly increased in
UCP3 null animals compared to wild-type animals.20 In addition to preventing
“endogenous” reactive oxygen species production by the mitochondria, UCPs may also
detoxify “exogenous” reactive oxygen species. Specifically, overexpression of UCP1 in
cultured cardiac myocytes protects against apoptosis induced by the addition of hydrogen
peroxide.23
This role in mediating reactive oxygen species production has led to the
hypothesis that the UCPs protect against oxidative damage. This has been best
established in the neurologic system.21, 22 However, as discussed below, this effect has
also been demonstrated in pathologic states in the heart, such as ischemia/reperfusion
injury, and may be relevant to other clinical scenarios such as heart failure and druginduced cardiotoxicity (e.g. doxorubicin).
UCPs in Reperfusion, Ischemia, and Atherogenesis
As mentioned above, UCPs may perform essential functions in ischemic heart
disease. In fact, increasing UCP expression in the heart may be a useful therapeutic
strategy as multiple studies have demonstrated a significant protective effect of the UCPs
in cardiac ischemia/reperfusion injury.4 For example, H9c2 cells overexpressing UCP1
were more likely than their “wild-type” counterparts to survive hypoxia/reoxygenation
exposure.24 Similarly, overexpression of UCP1 in isolated perfused mouse hearts
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improved functional recovery (as measured by contractility and oxygen consumption)
after ischemia and reperfusion.25
Consistent with their potential role in limiting oxidative damage in “at-risk”
myocardium, the UCPs have been observed to increase in cardiomyocytes adjacent to
regions of recent infarction. In a study of post-MI ventricular dilation, myocardial
infarction was induced in Sprague-Dawley rats resulting in a 60% increase in left
ventricular end-diastolic dimension. The authors noted an almost two-fold increase in
UCP2 mRNA expression in the tissue surrounding the infarct zone compared to shamoperated rats.26 They hypothesized that this increased UCP expression may be
contributing to the pathologic remodeling process by inducing a low-energy state in the
surviving myocardium. However, given the cardioprotective data reviewed above, it
seems more likely that UCP upregulation prevented further myocyte death through
limiting oxidative damage in the vulnerable peri-infarct region. It is of interest to note
that another “low-energy state”, fasting, is associated with an increase in UCP2 and
UCP3 expression, suggesting that the energy wasting effect of these UCPs is negligible.27
In addition to preventing cell damage and death due to the increased oxidative
stress of reperfusion, there is evidence supporting the theory that the UCPs protect the
heart during the preceding periods of ischemia. A recent study has demonstrated a direct
correlation between the level of UCP2 and UCP3 expression and the degree of ischemic
preconditioning attained by rat cardiomyocytes.28 The authors further observed that UCP
mRNA and protein expression were inversely associated with infarct size, and that UCP
depletion (with RNAi) attenuated or abolished myocyte recovery in vitro after anoxic
insult.
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In addition to protecting the heart from both ischemic and reperfusion-induced
damage, UCPs may prevent ischemia entirely, through limiting atherosclerotic plaque
formation. Reconstitution of the bone marrow of irradiated LDL-receptor deficient mice
fed a high-cholesterol, atherogenic diet with UCP2 null bone marrow cells has been
shown to result in larger atherosclerotic lesions in the aorta.29 It is believed that the UCP2
null monocytes created by the bone marrow transplantation produce more hydrogen
peroxide than wild-type monocytes. This increase in hydrogen peroxide production
results in greater vascular inflammation and endothelial cell activation, important initial
steps in atherogenesis. Also supporting this theory that UCPs protect against
atherosclerotic plaque formation, a common single nucleotide polymorphism (-866
GÆA) of the human UCP2 gene has been shown to be associated with the presence of
carotid atherosclerosis.30 Furthermore, individuals homozygous for this allele had double
the risk for coronary heart disease as compared to people with the alternate allele.31
Heart Failure and ROS
The observations discussed above suggest a significant role for UCPs in
protecting the heart from atherosclerosis, ischemia, and ischemia/reperfusion injury.
Other research has demonstrated a clear association between ROS and the development
of heart failure (implying a possible further connection between UCPs and CHF).32, 33 In
patients with heart failure, markers of increased oxidant stress have been demonstrated in
both pericardial fluid and blood.34, 35 Furthermore, alterations in the ability to regulate
oxidant stress are often present. Specifically, in failing hearts, decreases in the expression
and activity of enzymes involved in the detoxification of reactive oxygen species,
including catalase and manganese superoxide dismutase, can be observed.36, 37 While
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these changes may be the result, rather than the cause of heart failure, the observed
association between genomic changes in the expression of the detoxification enzymes
and the risk of heart failure suggests a genetic predisposition, and a causal relationship.
For example, polymorphisms in genes coding for superoxide dismustase are associated
with an increased risk for the development of idiopathic dilated cardiomyopathy.38-40
Reactive oxygen species also contribute to the progression of heart failure. In
addition to the serum markers of oxidant stress, increased levels of reactive oxygen
species have been reported in heart tissue samples from patients with longstanding
congestive heart failure.37 In a study of the role of reactive oxygen species in established
heart failure (in patients with hypertrophic cardiomyopathy), endomyocardial biopsy
samples demonstrated that lipid peroxidation, a marker of oxidative stress, was
significantly elevated as compared to individuals without heart failure.41 Furthermore,
this level of lipid peroxidation was directly correlated with both left ventricular enddiastolic diameter and end-systolic diameter, and inversely correlated with left ventricular
ejection fraction. Taken together, these data suggest a possible pathophysiologic role for
oxidative stress in the development and progression of heart failure.
With this background, the importance of decreasing oxidant stress in the failing
heart is easily understood. The efficacy of many proven heart failure therapies involves,
at least in part, protection of the myocardium from the detrimental effects of ROS. It has
been suggested that the beneficial effects of angiotensin converting enzyme inhibitors
(ACEI) in diabetic cardiomyopathy are related to the inhibition of ROS production.42
This mechanism is supported by the existence of substantial evidence that ROS are
involved in the development of diabetic heart failure.43, 44
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Additionally, as a therapy for non-diabetic as well as diabetic heart failure, it
appears that carvedilol derives some of its effectiveness through its potent antioxidant
properties.45 In one study utilizing an ischemic rabbit heart model, carvedilol, in
comparison to bisoprolol (a beta-blocker without antioxidant properties), led to markedly
decreased cardiac membrane lipid peroxidation.46 In non-ischemic rabbit model of CHF,
carvedilol treatment decreased measurements of oxidant stress (GSH to GSSG ratio) and
attenuated ventricular remodeling, cardiac hypertrophy, and myocyte apoptosis whereas
propranolol and doxazosin (which did not alter oxidative stress) had little effect.45
Other animal studies have confirmed the role of ROS in the development and
progression of heart failure. A transgenic mouse model with heart and skeletal musclespecific loss of manganese superoxide dismutase develops progressive congestive heart
failure with specific molecular defects in mitochondrial respiration.38 In this model,
oxidative stress causes specific morphologic changes in the mitochondria, with excess
formation of the reactive oxygen species, superoxide radical, reduction of ATP content,
and transcriptional alterations of genes associated with heart failure. Conversely,
overexpression of genes involved in the detoxification of reactive oxygen species, such as
glutathione peroxidase, improved left ventricular function in mice following myocardial
infarction.47 As discussed below, animal studies of heart failure, including transgenic
mouse models, have suggested that UCPs may be important in the response of the cardiac
myocyte to oxidant stress. Given the robust evidence for ROS as a pathophysiologic
mediator in the development and progression of heart failure, upregulation of UCPs may
be a potential target for heart failure therapy.
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UCPs in Heart Failure
In developed countries, the most common cause of heart failure is ischemic heart
disease. Depending on the study population and the method of investigation, the etiology
of heart failure is attributed to previous myocardial infarction in approximately 50% of
cases.48 Given the previous discussion of the role of UCPs in the prevention of ischemic
injury it is easy to see how these proteins might also be relevant to heart failure (by
preventing ischemic damage to the myocardium through slowing atherosclerosis as well
as decreasing oxidant stress in ischemic/reperfused cardiomyocytes, UCPs prevent a
major cause of heart failure). In addition, prior studies have demonstrated that the UCPs
are downregulated, at least on the mRNA level, in the failing heart, suggesting that their
downregulation may play a role in the development and/or progression of the disease (a
hypothesis that would fit nicely with the evidence reviewed above implicating increased
ROS as a mediator of CHF development and progression—i.e. decreased
UCPÆincreased ROSÆ CHF).11, 49, 50
As discussed above, mice with cardiac deletion of manganese-superoxide
dismutase develop heart failure from oxidative damage.38 In addition to the findings of
enhanced oxidant stress, the authors also noted that there was decreased cardiac
expression of UCP3, perhaps contributing to the pathologic process.
However, controversy remains as to whether UCPs play a beneficial or
detrimental role, particularly in the setting of heart failure, because downregulation of
UCPs in the failing heart could have theoretically opposing effects. A decrease in UCP
expression would be expected to enhance the coupling between citric acid cycle flux and
mitochondrial ATP synthesis, enhancing energetic efficiency. This effect would be
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potentially important in cardiomyocytes that are energetically stressed through the many
effects of heart failure. However, deceased UCP expression would also have the
counterbalancing effect of allowing greater production of reactive oxygen species.
The question then becomes one of whether downregulation of UCP expression in
the failing heart is beneficial or detrimental and should therapies be developed to increase
or decrease UCP expression. Would the shunting of protons away from ATP production
by increasing UCP expression contribute to a low-energy state?51, 52 Given the
preponderance of evidence implicating increased ROS in the pathogenesis of heart
failure, it would seem that limiting oxidative stress would be the more pressing goal.
Addtionally, it has been argued that, in addition to preventing oxidant stress and
cardiomyocyte damage, the metabolic effects of the UCPs are actually beneficial to the
failing heart, and represent an adaptive response to lipid accumulation within the
mitochondria and subsequent toxicity, and not a maladaptive response.53 Finally, one
cannot ignore the evidence suggesting that UCP upregulation would prevent heart failure
development through limiting ischemic damage.
Whether the decreased UCP expression in CHF is a protective response or a
pathophysiologic one, it seems clear that the UCPs are intimately involved in the
development and pathogenesis of heart failure.
Clinical Relevance
From a review of the literature, it seems clear that UCPs play an important role in
two exceptionally important cardiovascular conditions: ischemic heart disease and heart
failure. Ischemic heart disease causes more deaths and disability and incurs greater
economic costs than any other illness in the developed world. In the United States, it is

15
estimated that more than 12 million people are afflicted with this disease. With the
increasing rates of obesity, insulin resistance, and type 2 diabetes mellitus—all clearly
linked to the development of heart disease—it is projected that the rates of ischemic heart
disease will only continue to increase, likely becoming the most common cause of death
worldwide by 2020.54
Like ischemic heart disease, congestive heart failure is a common and often
devastating disease of great importance to the world health community. Heart failure is a
common disease with a prevalence estimated at 1-2% in the general population.55
Increasingly important as our population ages, this condition can afflict upwards of 710% of the elderly and is often underdiagnosed.56 A diagnosis of heart failure is not a
trivial matter with one year mortality rates estimated to be between 12 and 45% and
worse long-term survival than most common cancers.57, 58, 59 The substantial prevalence
and significant complications of heart failure make it a source of major healthcare
expenditure to the population at large. In the United States, more than 900,000 people
are hospitalized each year for heart failure, creating annual expenses in excess of 6 billion
dollars.60 Given the important roles of the UCPs in common and devastating clinical
diseases, a clear understanding of the regulation of these proteins would be extremely
valuable in developing new potential therapies.
Regulation of UCPs
While the mechanisms responsible for regulating UCP expression in various
tissues (including skeletal muscle, hepatocytes, pancreatic β-cells, and adipocytes) have
been well studied, the regulation of UCP in the heart is not yet as well characterized. Data
suggests that UCP expression in the heart is regulated, in part, through peroxisome
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proliferator-activated receptor (PPAR) α-mediated mechanisms.61 In a mouse heart
model, PPAR α agonist WY-14,643 increased cardiac UCP2 and UCP3 protein in wild
type mice but not in PPAR α -/- mice.62
In addition to the PPAR pathway, there is evidence that UCP expression can be
increased in skeletal muscle through activation of AMP-activated protein kinase
(AMPK), a signaling protein kinase that responds to metabolic stress. 63, 64 In one study,
rats were injected with an AMPK activator (AICAR, described in detail below) for 28
days after which analysis of skeletal muscle revealed increased levels of UCP3 mRNA
and protein. Another study utilizing an AMPKα2 knock out model demonstrated
decreased levels of UCP3 mRNA content.65 Prior to our experiments, it remained unclear
whether these observations in skeletal muscle were applicable to the heart as well.
Because of this uncertainty, and the potentially important clinical implications, it is the
potential role of AMPK in the regulation of cardiac UCPs that is the focus of this
research.

AMP-activated Kinase
Structure and Function
AMP-activated kinase (AMPK) is a heterotrimeric protein kinase that serves as a
key energy regulator in the eukaryotic cell. First described in the late 1980s, AMPK has
been implicated in a vast number of metabolic functions.66 Chiefly, AMPK responds to
changes in the energy stores of the cell by enhancing nutrient uptake, increasing the
provision of energy, as well as decreasing energy-depleting cell activities with the
combined result of restoring cellular energy balance.67 This function has led some to
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describe AMPK as the “fuel gauge” of the mammalian cell and the “guardian of energy
status” in the heart.68, 69
The AMPK protein is a complex of three subunits: the catalytic α subunit, and the
regulatory β and γ subunits. Each of these subunits has two or three isoforms, and twelve
different isoform combinations appear to be stable as the functional heterotrimeric
complex.70, 71 However, the majority of cardiac myocyte AMPK appears as an α2β1γ1
combination, with lesser contributions from α1, β2, γ2, and γ3.72, 73 The expression of
different isoforms is tissue dependent, with γ3, for example, predominating in skeletal
muscle but being absent in the heart.68 Apart from the relative prevalence within specific
tissues, some differences between the various isoforms have been described; specifically,
variations in cellular localization and in response to cellular AMP levels.70 For example,
AMPK complexes containing the α2 isoform are preferentially localized within the cell
nucleus whereas the α1-containing complexes are absent from this compartment.74
As briefly mentioned above, AMPK functions chiefly as an energy sensor and
metabolic regulator. AMPK is activated when there is an increased AMP:ATP ratio—that
is, when energy stores are low. AMP allosterically activates AMPK while also inducing
phosphorylation of a threonine residue in the α subunit (Thr 172) by upstream kinases.67
The AMPK kinases (AMPKK) include the tumor suppressor LKB1 as well as calcium
calmodulin dependent kinase (CaMKK).75, 76 (Interestingly, the CaMKK pathway appears
to respond to increased intracellular calcium concentrations rather than AMP:ATP ratio
and may be an alternative mechanism by which tissue specific regulation is achieved.)
In addition to inducing phosphorylation (and thus activation) of the α subunit,
high levels of AMP prevent dephosphosphorylation and subsequent deactivation of the
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AMPK complex.77 Both the phosphorylation of AMPK by the upstream AMPKK and the
inhibition of the AMPK phosphatases are prevented by increased concentrations of ATP.
Thus it is the AMP:ATP ratio that ultimately controls the regulation of AMPK (as an
aside: it has been shown that AMPK also responds to indirect signals of energy status,
including glycogen levels—the β subunit of the AMPK protein has a glycogen binding
domain that responds to high cellular glycogen levels [indicative of adequate energy
stores] by inhibiting AMPK activation.68, 78). Perturbations in the AMP:ATP balance can
be caused by physiologic mechanisms (such as exercise) or pathologic stimuli (e.g. heat
shock and metabolic poisoning which limit ATP production, or ischemia and hypoxia
which increase ATP consumption).70 Previous research has clearly demonstrated that
AMPK responds to a variety of these metabolic stressors, including hypoxia, ischemia,
and oxidative stress.67
These physiologic stimuli perturb the “resting” balance of AMP relative to ATP.
AMP is present in the heart in very low concentrations under normal physiologic
conditions. During periods of ischemia or other types of metabolic stress, the amount of
ADP rapidly increases.68 In eukaryotic cells, a very active adenylate kinase enzyme
maintains an equilibrium between ADP and AMP by catalysis of the reaction
2ADPÆATP+AMP. Thus an increase in ADP leads to a quick corresponding increase in
AMP, and the AMP:ATP ratio varies as approximately the square of the ADP:ATP
ratio.70 This leads to an exquisitely sensitive mechanism for sensing the energy status of
the cell.
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Figure 2. AMP-activated Kinase (AMPK) regulation and function. An increased AMP:ATP ratio indicates
a negative energy balance in the cell and induces phosphorylation of a threonine residue on the catalytic α
unit of AMPK by upstream AMPK kinases (e.g. LKB1). The activated AMPK phosphorylates various
downstream targets with the net result of increasing cellular energy production while limiting cellular
energy-expenditure

In response to depleted energy stores, AMPK has a range of effects on tissues
throughout the body with the goal of limiting ATP consumption while increasing its
production to restore cellular energy balance. While many of the molecular pathways
remain to be elucidated, it is clear that AMPK phosphorylates a range of target proteins,
“switching on catabolic pathways that generate ATP, while switching off anabolic
pathways and other nonessential ATP-consuming processes.”70 The energy-expending
processes that AMPK activation limits include fatty acid, cholesterol and protein
synthesis. This occurs through a combination of direct protein modification as well as
modulation of cellular genetic expression.70 In the heart, AMPK activation increases fatty
acid oxidation and glycolysis as well as glucose uptake by cardiomyocytes.79 Similar
effects are observed in skeletal muscle. In the liver, fatty acid synthesis, cholesterol
synthesis and gluconeogenesis are inhibited by AMPK activation. Fatty acid synthesis
and lipolysis are also decreased in adipocytes. And in the hypothalamus, appetite is
stimulated.69 The end result of this regulation is to conserve energy within the cell during
times when stores are low.
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As stated previously, the exact mechanism of action of many of these pathways
has yet to be fully defined. It seems likely that many of these effects are mediated
through signaling cascades involving protein phosphorylation by the AMPK enzyme, but
some degree of transcription factor modification and differential gene expression is likely
as well. The uncertainty surrounding the downstream effectors of the AMPK pathways
make this research project an important endeavor, particularly because AMPK has
already been proven to exert important protective effects in the heart, and a more clear
understanding of signaling pathways would allow for potential pharmacologic
manipulation.
AMPK and the Heart
Previous research has demonstrated that AMPK is important in maintaining
cardiovascular energy balance. Under normal physiologic conditions, AMPK plays a role
in controlling both skeletal and heart muscle metabolism during exercise.68, 80 Under
pathologic conditions, AMPK activation leads to translocation of cardiac GLUT4 glucose
transporters to the sarcolemma and a subsequent increase in cellular glucose uptake.68, 81
In the ischemic heart, this transition from fatty-acid based metabolism to a greater
reliance on glucose as an energy source is key to cell survival as nutrients become more
scarce. 81 In addition, AMPK has been shown to be critical to maintaining myocardial
energy homeostasis during ischemia by stimulating glycolysis.82, 83
Past research in our lab has indicated an important role for AMPK in the
myocardial response to ischemia. To better characterize the function of AMPK during
ischemic and post-ischemic reperfusion conditions, transgenic mice with a kinase dead
(KD) form of the AMPK protein were utilized in a series of experiments. During low-
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flow ischemia and post-ischemic reperfusion in vitro, KD hearts failed to augment
glucose uptake and glycolysis, although glucose transporter content and insulinstimulated glucose uptake were normal. KD hearts also failed to increase fatty acid
oxidation during reperfusion. Furthermore, KD hearts demonstrated impaired recovery of
LV contractile function during postischemic reperfusion that was associated with a lower
ATP content and increased injury compared with wild type hearts. These data suggest
that AMPK is responsible for activation of glucose uptake and glycolysis during lowflow ischemia and that it plays an important protective role in limiting damage and
apoptotic activity associated with ischemia and reperfusion in the heart.79
AMPK and the UCPs
AMPK activation has additional effects that are related to regulation of key
proteins on a transcriptional level. One important effect of AMPK activation in skeletal
muscle is an increased expression of the UCPs as well as other key metabolic proteins,
including hexokinase II and GLUT4.81, 84-86 In addition, AMPK activation has been
shown to be a critical step in the regulation of several nuclear transcription factors,
including NRF-1, HIF-1α and p300.84, 87, 88 These observations suggest that AMPK may
exert some of its metabolic effects through direct modification of genetic expression in
the nucleus.86
While AMPK activation has been shown to upregulate both UCP3 mRNA and
protein expression in rat skeletal muscle, a similar association has not been demonstrated
in the heart. There is some circumstantial evidence that implies such a role. For example,
PPARγ agonists have been shown to activate AMPK, probably through a mechanism that
involves increasing the cellular AMP:ATP ratio.89 PPAR pathways are also involved in
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the upregulation of UCPs, though most evidence for the cardiac UCPs supports a role for
PPARα rather than PPARγ (which has been shown to activate UCPs in tissues outside the
heart).90-92
Given the potential role for UCPs in protecting the cell from oxidative stress, an
association between increased ROS load and AMPK activation would seem to suggest a
possible regulatory link. In a series of experiments with NIH-3T3 cells, H2O2 induced
phosphorylation at the Thr172 activation site of AMPK. This activation was blocked by
pretreatment with 0.5% dimethyl sulfoxide, a potent free-radical scavenger.93 Others have
suggested that AMPK may have an as yet unidentified role in the prevention of reactive
oxygen species generation.68 These observations favor a potential role for AMPK in the
regulation of UCPs: decreased energy or increased reactive oxygen species leading to
AMPK activation would increase expression of the UCPs and prevent excess ROS
production as well as detoxify existing ROS. We set out to experimentally examine the
hypothesis that AMPK activation upregulates UCP transcription and translation, and to
more clearly define the mechanism by which this occurs.
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STATEMENT OF PURPOSE AND SPECIFIC AIMS

Mitochondrial uncoupling proteins appear to play critical roles in cardiovascular
metabolism, in protection of the heart during periods of ischemia and post-ischemic
reperfusion, and in the pathogenesis and potential prevention of heart failure. A more
complete description of their regulation may lead to important advances in understanding
the pathophysiology of various heart diseases, and may contribute to the development of
promising, novel therapies. AMPK controls the metabolic state of virtually all
mammalian cells, including cardiomyocytes, and is activated under clinically relevant
stimuli that appear to also induce the upregulation of the UCPs in the heart (ischemia, for
example). Given these observations, it has been suggested that AMPK controls the
cardiac expression of UCPs. The set of experiments described in this thesis examined the
following hypothesis:

Activation of AMPK leads to an increased expression of the mitochondrial
uncoupling proteins, UCP2 and UCP3, in the cardiomyocyte.

Specific Aims:
1. To determine whether pharmacologic activation of AMPK induces an increase in
UCP2 and UCP3 mRNA utilizing both isolated tissue and cellular cardiomyocyte
models.
2. To determine whether pharmacologic activation of AMPK induces an increase in
UCP2 and UCP3 protein in a cellular cardiomyocyte model.
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3. To identify any sites of interest in the UCP3 promoter where AMPK, or its
downstream mediators, may interact to affect an upregulation of UPC3
transcription and translation.
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METHODS

Pharmacologic AMPK activation
To determine whether mitochondrial uncoupling proteins in the heart are
upregulated via a mechanism involving the activation of AMPK, a series of experiments
were planned utilizing a pharmacologic activator of AMPK. While AMPK is usually
activated by an increased AMP:ATP ratio as described above, alterations in this ratio are
often impractical for experimental investigations. AMPK can be pharmacologically
activated through the addition of 5-aminoimidazole-4-carboxamide riboside (AICAR).
AICAR is a cell-permeable adenosine analog that is taken up by the cells and
phosphorylated to form 5-aminoimidazole-4-carboxamide-1-d-ribofuranosyl-5′monophosphate (ZMP), an AMP mimetic.67 ZMP mimics all of the activating effects of
AMP, although it is much less potent on a mol:mol basis.70, 94 AICAR also blocks
adenosine re-uptake (as described in more detail below) and this was the motivation
behind its previous use in clinical trials.
Throughout all of the experiments described below, AMPK activation was
achieved using AICAR. In all cases, the activation of AMPK was confirmed by
evaluation of Thr172 phosphorylation by immunoblot analysis. As described above,
phosphorylation of the threonine-172 residue on the α-subunit by upstream AMPKK is a
critical step in the activation of the AMPK complex, and phosphorylation is an accepted
marker of enzyme activation.
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Tissue Model
To examine the role of AMPK in the regulation of cardiac UCP expression, a
mouse tissue model was used first. C57/BL6 wild-type mice were sacrificed using
pentobarbital (150 mg/kg, i.p.) and the hearts were harvested and immediately placed in
ice-cold 0.9% saline. The ventricles were isolated by trimming away any remnants of the
great vessels as well as the atria. The remaining tissue was placed in an acrylic mouse
brain slicer with 1.0-mm coronal slicing intervals. The heart was then cut into 1-mm thick
rings that were then placed in 100-mL Erlenmeyer flasks with either a control buffer
solution or an “experimental” AICAR solution as described below.

Figure 3. Schematic Representation of Tissue Model Experiments. C57/BL6 wild type mouse ventricles
were harvested, sectioned, and incubated with or without AICAR. After homogenization, RNA was
isolated, and quantitative real time PCR performed to determine relative expression of UCPs.

The basic incubation solution consisted of 1x Dulbecco’s phosphate buffered
saline (DPBS) with 1 mM calcium chloride, 1 mM magnesium chloride, 1% bovine
serum albumin (BSA), 5 mM glucose and 0.4 mM oleate. To make the control solution, 5
μl of DMSO was added (as a vehicle control) to 5 ml of the incubation solution described
above. The “experimental” solution was identical except that 25 μl of 200 mM AICAR
was added to the 5-mL of incubation solution to yield a 1 mM concentration of AICAR.
The heart slices were incubated in either control solution or AICAR solution on a
shaking water bath at 37°C with 100% oxygen for 1 hour or 24 hours. At the end of the
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incubation, the ventricular slices were snap frozen in liquid nitrogen and stored at -80°C
until analysis.
Frozen sections were homogenized using a rotor-stator homogenizer followed by
5 passes through a 20-gauge needle. RNA was then isolated using the RNeasy mini kit
(Qiagen) using the protocol suggested by the manufacturer. RNA concentration was
determined spectrophotometrically as A 260/280.
Using the RNA samples, reverse transcription PCR was performed to determine
the relative expression of UCP2 and UCP3 mRNA. RNA was diluted to 1 µg/11 μl
concentration. For each reaction, 11 μl of the RNA mixture was added to 1 μl of
oligo(dT)15 primer (Promega) and mixed. Reverse transcription mastermix was prepared
(per reaction: 4 μl of 5x first strand synthesis buffer [Roche] + 2 μl of 0.1 M DTT
[Roche] +1 μl of 10mM dNTPs per reaction [Roche]). Seven microliters of this reverse
transcription mastermix was added to each reaction and incubated at 42°C for 2 minutes.
One microliter of Superscript II (Roche) was added to each reaction and the mixture
returned to 42°C incubation for another 50 minutes. The mixture was then incubated at
70°C for 15 minutes. RNase H (0.6 μl, Roche) was added to each sample and then
incubated for 20 minutes at 37°C. The total volume was adjusted to 100 μl by adding 79
μl of sterile water, and the sample was boiled for 10 minutes. The sample was
immediately placed on ice and used immediately in PCR reactions, or stored at -80°C.
The cDNA from the RT-PCR described above was used for qualitative real time
PCR (qRTPCR) reactions as follows: primers and Taqman probes using a “fam” dye
were created (Biosearch Technologies) using sequences previously published in the
scientific literature.61

Formatted: Bullets and
Numbering
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GENE

PRIMER/

SEQUENCE

PROBE
rat/mouse UCP2

rat UCP3

Forward

5'-TCATCAAAGATACTCTCCTGAAAGC-3'

Reverse

5'-TGACGGTGGTGCAGAAGC-3'

Probe

5'-FAM-TGACAGACGACCTCCCTTGCCACT-TAMRA-3'

Forward

5'-GTGACCTATGACATCATCAAGGA-3'

Reverse

5'-GCTCCAAAGGCAGAGACAAAG-3'

Probe

5'-FAM-CTGGACTCTCACCTGTTCACTGACAACTTCCTAMRA-3'

mouse UCP3

Forward

5'-TGCTGAGATGGTGACCTACGA-3'

Reverse

5'-CCAAAGGCAGAGACAAAGTGA-3'

Probe

5'-FAM-AAGTTGTCAGTAAACAGGTGAGACTCCAGCAATAMRA-3'

rat/mouse cyclophilin

Forward

5'-CTGATGGCGAGCCCTTG-3'

Reverse

5'-TCTGCTGTCTTTGGAACTTTGTC-3'

Probe

5'-FAM-CGCGTCTGCTTCGAGCTGTTTGCA-TAMRA-3'

Table 1. Taqman Primers and Probes for quantitative Real Time PCR. Mouse primers and probes were
used for tissue model experiments (mouse ventricle) while rat primers and probes were used for cellular
model experiments (H9c2 cells). Table adapted from Young, ME, et. al.61

For the qRTPCR experiments, cyclophilin was selected as a reference
“housekeeping” gene on the basis that it is present in the cells of interest and thought to
be unaffected by treatment with AICAR. In addition, previous work by others in the lab
had demonstrated that the amplification efficiencies of the cyclophilin reference gene and
the target UCP2 and UCP3 genes are similar. This observation is critical for meaningful
analysis with the delta-delta method (described in detail below).
A “primer-probe” mix was prepared for each gene of interest (for example,
UCP2, UCP3 and cyclophilin) with 5 μl of 100 µM probe, 10 μl of 100 µM forward
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primer, 10 µl of 100 µM reverse primer, and 375 µl of DNAse/RNAse free water. Eight
μl of cDNA was mixed with this primer-probe mix and 12.5 µl of taqman mastermix
(Applied Biosystems).
The qRTPCR was conducted with a DNA Engine Opticon 2 two-color PCR
Detection System (Bio-Rad) connected to a standard IBM desktop computer. A typical
qRTPCR protocol was employed (e.g. incubation at 95°C for 5 minutes followed by 50
cycles of 95°C for 30 seconds, 60°C for 1 minute, and a plate reading). Quality control
for the specificity of the amplification product was achieved through gel analysis
revealing a single band of appropriate size.
Results were analyzed using the “delta-delta” or “comparative Ct” method. A
“threshold value” is arbitrarily set along the logarithmic portion of the amplification
curve. The cycle at which the sample crosses the threshold (or Ct value) is recorded for
each sample, including the reference gene samples. The target samples, both
experimental and control (in this case AICAR treated and control incubation buffer
treated, respectively) are each normalized to the reference gene by subtracting the Ct of
the reference sample from the Ct values of the experimental samples yielding ΔCt’s for
each of the target samples. As mentioned above, it is critical that the sample gene has an
amplification frequency similar to the chosen reference gene—that is, that the slope of
the logarithmic portion of the curve is similar. If this is not the case, than normalization to
the reference gene will introduce error into the analysis and make meaningful comparison
impossible.
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After normalizing to the reference gene, the “delta delta” value is then calculated
by subtracting the ΔCt of the mean value for the control sample from the ΔCt of each
experimentally treated sample. Expressed mathematically, the calculation is as follows:
delta delta Ct= ( Ctexperimental - Ctreference ) - ( Ctcontrol - Ctreference )
If the amplification efficiencies are similar, this value is an expression of the quantitative
amount of cDNA that was present at the start of the qRTPCR procedure—that is, the
relative expression of the gene of interest. To complete the determination of relative gene
expression, the following calculation is performed:
relative mRNA = 2-delta delta Ct
In this set of experiments, cDNA from the AICAR treated and “control” (or nonAICAR treated) ventricular samples was analyzed as above. Mean expression values
were calculated for both experimental and control samples and paired student t-tests were
used to determine statistical significance (GB-Stat PPC SchoolPak).

Cellular Model
Next, experiments were performed utilizing a cellular model. The cellular model
was used to further support a role for AMPK in the regulation of UCP expression
(including important quantification of UCP protein levels as well as mRNA) and to
perform the genetic studies outlined below.
H9C2 cells were selected because of their rapid doubling time, ease of use, and
similarity to adult cardiomyocytes. The cells are derived from a neonatal rat myoblastic
line and retain some of the characteristics of true cardiomyocytes. Unlike
cardiomyocytes, however, H9C2 cells need not be isolated from harvested tissue, are far
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easier to maintain, and replicate indefinitely.95 For these experiments, the cells were used
from passage 1 through passage 15 and then discarded because later generations can
develop morphology significantly different from typical cardiomyocytes.

Figure 4. Schematic Representation of Cellular Model Experiments. H9C2 Cells were incubated with or
without AICAR. In one set of experiments mRNA was isolated and then used for quantitative real time
PCR to determine UCP expression in AICAR treated vs. control cells. In a second set of experiments, cells
were harvested and protein isolated to determine phospho-AMPK and UCP expression in AICAR treated
vs. control populations.

Cells were plated under sterile conditions onto 100-mm tissue culture plates with
high glucose, L-glutamate containing Dulbecco’s Modified Eagle Medium (Gibco)
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) and a 1% penicillinstreptomycin antibiotic mixture. Subconfluent (70-80%) plates were passaged in a typical
manner (cells were detached from plates by addition of trypsin, which was subsequently
inactivated by addition of 5 ml of DMEM/10% FBS media; the cells were then collected
and sedimented by centrifugation, resuspended in fresh media, and aliquoted onto new
plates). All cells were stored in a sterile incubator at 37°C and 5% CO2.
Originally, there was some concern that the 10% FBS media might contain
growth factors or other substances that would affect AMPK activation and introduce error
to the planned experiments. Therefore, H9C2 cells were incubated with either high
glucose (4.5 g/l) or low glucose (1 g/l) DMEM with 0.1% or 1% FBS for 24 hours prior
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to harvest and immunoblots for phospho-AMPK were performed to determine if these
culture conditions activated AMPK (described below). However, all combinations of
low-FBS media led to super-activation of AMPK such that no difference between
AICAR treated and control samples could be determined (all samples were maximally
phosphorylated). A decision was therefore made to incubate all cells with 10% FBS for
the entirety of the experiments.
The H9C2 model was used to examine the effect of AMPK activation on UCP2
and UCP3 mRNA levels in a manner similar to the tissue model experiments described
above. When 70-80% confluent, H9C2 cells were washed with DPBS, then treated with 1
mM AICAR in 5-ml of 10% H9C2 media (as described above) or with 5-ml of media
alone for 1 hour or 24 hours. The cells were again washed with DPBS and harvested as
per the “cells” protocol in the RNeasy minikit (Qiagen). RNA concentration was again
determined spectrophotometrically, and reverse transcription PCR was performed in the
same manner as described above. Using this cDNA, qRTPCR was then performed as
previously described. Analysis was again performed using the Opticon 2 (Bio-Rad)
system and the “delta delta” method.
To verify that AICAR was in fact activating AMPK, immunoblotting for
phospho-AMPK was performed. H9C2 cells that were 70-80% confluent were washed
with cold DPBS. Vacuum suction was then employed to remove all DPBS. Lysis buffer
mix was prepared by combining 10-ml of CellLytic M Cell Lysis reagent (Sigma), 1
Complete Proteinase Inhibitor complex tablet (Roche), 100 µl of 1 M sodium fluoride,
and 10 µl of 1M sodium orthovanadate (Na3VO4). Two hundred microliters of this mix
was added to each plate. The plates were scraped and the cell lysate was transferred to a
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microcentrifuge tube. The mixture was centrifuged at 10,000g for 10 minutes. The
supernatant was removed and stored (precipitate was discarded) and the protein
concentration subsequently measured spectrophotometrically using the BradfordStandard method with a BSA standard.
Twenty micrograms of protein was combined with 5 µl of 6x protein loading
buffer and water (if necessary) to a total volume of 25 μl. This mixture was heated to
100°C for 10 minutes. The protein was then loaded into a 10% NuPage gel (Invitrogen)
with a kaleidoscope marker (Biorad) and electrophoresis carried out in MES containing
buffer for 35 minutes at 200V. The separated proteins were then transferred to a
nitrocellulose membrane (Millipore) by electroblotting at 250 mA for 1.25 hours. The
membrane was blocked in 5% BSA solution for 1 hour and then incubated overnight at
2°C with 10 µl of rabbit anti-phosphoAMPK antibody (Cell Signaling) in 10-ml of 5%
BSA. The next morning, the membrane was washed with tris-buffered saline with tween
(TBST) buffer three times for 15 minutes each. Secondary antibody (4-µl of donkey antirabbit IgG-HRP [Santa Cruz] in 5 ml of 2.5% BSA solution) was then added for 1 hour at
room temperature. The membrane was washed again 3 times for 15 minutes each. After
washing was complete, the membrane was incubated with Chemiluminescent Developer
Solution (Pierce) for 1 minute, and x-ray film (Kodak) placed in the developer cassette
with the membrane for approximately 15 minutes. The blot was then stripped to remove
the antibodies, washed two more times with TBST buffer and blocked in 5% milk for 1
hour. Then the membrane was incubated overnight at 2°C with 25 μl of goat anti-AMPK
α2 (R&D Systems) in 10 ml of 5% milk to confirm equal loading of samples. The next
morning the membrane was washed three times and then incubated with 4 µl of donkey
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anti-goat IgG-HRP (Santa Cruz). The membrane was again developed with detection
buffer and an x-ray film record obtained after approximately 10 minutes of exposure.
Immunoblots were later scanned into a computer. Band intensities from the images were
quantified using Image J (National Institutes of Health).

Expression of UCP mRNA and protein
There is some controversy in the literature as to whether UCP mRNA levels truly
correlate with protein expression.96, 97 For example, while UCP2 mRNA is found in adult
myocardium, skeletal muscle, and brown adipose tissue, UCP2 protein is generally not
detected in these tissues.97, 98 In recognition of this potential discrepancy, H9C2 cells
were treated with AICAR or control solution and then harvested for immunoblot analysis
of protein expression. Because the uncoupling proteins are found in the mitochondria, a
mitochondrial isolation protocol was employed to improve the detection of UCP2 and
UCP3 protein. Plates containing H9C2 cells that were 90-100% confluent were
trypsinized and the cells collected into centrifuge tubes (4 plates per tube) and spun at
600g for 5 minutes. The cells were washed with ice cold DPBS and then spun down
again after which the supernatant was discarded. This step was repeated a second time.
Approximately 1.5 ml of lysis buffer (5 ml of lysis reagent [Sigma], 1/2 of a Complete
Protease Inhibitor mini tablet [Roche], 500 µl of 1 M sodium fluoride, and 50 µl of 1M
sodium orthovanadate) was added to each tube. The samples were then incubated on ice
for five to ten minutes. At 1-minute intervals, the samples were mixed by drawing them
up and down 3 times through a 25-gauge needle into a 3 ml syringe. Three milliliters of
mannitol mitochondrial extraction buffer were added to each sample (extraction buffer
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contained 5 mM HEPES, 210 mM mannitol, 70 mM sucrose and 1mM EGTA). The
homogenate was centrifuged at 600g and 4°C for 10 min. The pellet was set aside for
nuclear protein isolation and subsequently stored for later analysis. The supernatant was
transferred to a fresh tube and centrifuged at 11,000g and 4°C for 10 min. The resulting
supernatant was then discarded and the pellet resuspended in a storage buffer and stored
at -80°C until analysis.
Immunoblot analysis was performed in a manner similar to that described above.
Electrophoresis was performed using 12% NuPage gels (Invitrogen) in MES buffer for 35
minutes at 200V. Transfer to the nitrocellulose membrane was carried out via the same
procedure as above. Blocking was achieved with 5% milk solution and the membranes
were incubated overnight in primary antibody solution (25 µl of rabbit anti-UCP2
[BioLegend] or 25 µl of anti-UCP3 [Affinity Bioreagents] in 5 ml of 5% milk).
Secondary antibody (4 µl of donkey anti-rabbit IgG-HRP [Santa Cruz]) was applied the
next day after washing, and development achieved as above with 20-30 minute
exposures. After stripping, washing and blocking in 5% milk for one hour, 10 µl of goat
anti-cytochrome C antibody in 10 ml of 5% milk was applied to the membrane (as a
loading control) and incubated overnight at 2°C. Secondary antibody (2 µl of anti-goat
IgG-HRP [Santa Cruz] in 10 ml of 2.5% milk) was then applied and the membrane
incubated at room temperature for one hour. Development (with approximately 2 minute
exposure) and analysis were carried out as above.
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Analysis of the Promoter Region of UCP3
In order to identify the promoter region of the UCP3 gene that interacts with
activated AMPK or one of its downstream messengers, luciferase reporter vectors were
created incorporating different portions of the UCP3 promoter.
The sequence of the 2100 bp segment preceding the start of transcription was
downloaded from GeneBank (NIH). Using computer software (Vector NTI [Invitrogen])
this promoter was analyzed and divided into three overlapping segments. The full 2000
bp sequence was termed “long,” the segment from -1977 to -1077 “left,” from -1600 to 697 “middle,” and -1000 to +20 “right.”

Figure 5. UCP3 Promoter Constructs. In order to better characterize the site of interaction between
activated AMPK and the promoter segment of the UCP3 gene, the 2000 bp segment preceding the start of
transcription was cloned, as were three “fragments” named “Left,” “Middle,” and “Right.”

Heart tissue from a Sprague-Dawley rat was used to extract DNA using a DNeasy
tissue kit (Qiagen). After obtaining all appropriate primers from the W. M. Keck
Foundation Biotechnology Resource Laboratory (Yale University), PCR of the
aforementioned DNA was employed to create the promoter constructs. The primers used
in this experiment are presented below in Table 2.
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Promoter
Name

Sequence

Tm

Length

Full
Promoter

PRU3F1
ACCCTCAGCCCTACCTGTCCCACAT
63
25
PRU3R1
CCGGAGATCTTACCTGTGAGTCTAGCCAAGGT
66
32
Left
PRU3F2
GCTTGAGAAATGTCAGCCCACACTT
60
25
PRU3R2
CCGGAGATCTTGACATAGAAGGGAGACTAAAA
63
32
Middle
PRU3F4
GCTGCAGGCAAAGTGGAGGTCTGAA
64
25
PRU3R4
CCGGAGATCTAGCAGGATCGTACAGAATGTAT
64
32
Right
PRU3F3
AAGGAATTCTGCTCACCTGCCCCTT
63
25
PRU3R3
CCGGAGATCTCCCCTCCTCACCATTCACTGTT
71
32
Table 2. UCP3 Promoter Primers for Fragment Construction. In order to create UCP3 promoter
“fragments,” the above PCR primers were designed using Vector NTI software (Invitrogen). All primers
also included a BglII restriction enzyme site to allow for easy transfer from the T-easy vector to the
pGL4.18 vector.

After PCR, all of the fragments were subsequently cloned into the pGEM T-easy
vector (Promega) and subcloned into the luciferase reporter vector pGL 4.18 (Promega).
Fragment presence, orientation, and quality (absence of nucleotide mismatches) were
confirmed by direct sequence analysis (Yale Keck Facility).
Together with pGL4.18/fragment transfection, H9C2 cells were transfected with
the pGL4.75 vector containing the CMV promoter to be used as a control. This control
plasmid was later used to normalize signal to the number of transfected cells. Briefly,
H9C2 cells were plated on 60-mm plates and transfected at 65-80% confluency. FuGene
6.0 (Roche) was used as a transfection reagent. Maximum transfection efficiency was
achieved by using 6 µl of FuGene 6.0 and 2 µg of target and 2 µg of control plasmid.
After transfection, half of the cells were treated with 1 mM AICAR while the
other half of the cells remained in control culture media. One hour later, all cells were
harvested with 300 μl of 0.25% trypsin/EDTA, centrifuged to sediment the cells,
resuspended in 100 µl of fresh media, and mixed with 100 µl of DualGlo (Promega)
luciferase reagent/buffer mixture as described in the kit’s instructions. After twenty
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minutes of incubation at room temperature, chemiluminescence was measured using a
luminometer (Turner Designs). Results were recorded and 100 µl of 1:100 Stop and Glo
(Promega) reagent/buffer mixture was added to each sample. The samples were incubated
at room temperature for an additional twenty minutes after which luminescence was
measured again. The firefly luciferase chemiluminescence (measured after DualGlo
reagent addition) revealed UCP3 transcription in response to AMPK activation or in the
absence of this stimulus (control). The CMV Renilla promoter-driven luciferase,
measured after addition of Stop and Glo reagent, served as a control to standardize data
between samples. Luciferase chemiluminescence for each sample was normalized to
CMV Renilla chemiluminescence for the same sample to control for transfection
efficiency and cell number. The normalized data from experimental samples were then
compared to control samples for the same promoter fragments and a relative expression
calculated.

Statistical analysis
Data are reported as mean values +/- standard deviation. Means were compared to
control values and to each other with student’s t-tests (GB-Stat PPC SchoolPak) and twotailed p-value less than 0.05 was considered statistically significant.
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RESULTS

Activation of AMPK by AICAR
As discussed above, phosphorylation of the threonine-172 residue of the αsubunit of AMPK is necessary for covalent enzyme activation. As was expected, AICAR
induced phosphorylation (and activation) of AMPK at both one and twenty-four hours of
treatment in H9C2 cells. These data confirm that AMPK is activated under the
experimental conditions in which UCP mRNA and protein expression were to be
evaluated.

Figure 6. AMPK activation as a result of 1 hour of AICAR treatment. Phosphorylation of the Thr172
residue of the AMPKα subunit is indicative of activation. Treatment of H9C2 cells and subsequent protein
isolation and immunoblotting demonstrated that pAMPK levels were significantly increased in AICAR
treated samples as compared to controls after 1 hour of treatment. pAMPK density was normalized to
Actin. N=5.
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Figure 7. AMPK activation as a result of 24 hours of AICAR treatment. After 24 hours of treatment of
H9C2 cells with AICAR a significant difference in Thr172 phosphorylation (AMPK activation) is
observed. pAMPK density was normalized to Actin. N=5.

AICAR effect on UCP mRNA in mouse ventricle
In the isolated tissue model utilizing mouse ventricular slices, activation of
AMPK by AICAR induced significant increases in UCP2 and UCP3 mRNA at both the
1-hour and 24-hour time points. Interestingly, there was a much greater increase in the
expression of UCP3 mRNA after 24 hours of AMPK activation when compared to UCP2
mRNA. These data suggest that AMPK activation may play a role in upregulating the
expression of the mitochondrial uncoupling proteins in the heart.

Figure 8. Mouse ventricle incubation with AICAR leads to increased UCP2 and UCP3 mRNA levels.
Isolated 1 mm slices of mouse ventricle were incubated in a buffer solution with or without AICAR. After
1 hour or 24 hours, samples were snap frozen in liquid nitrogen and subsequently mRNA isolated from
them. qRTPCR was performed yielding data as summarized above. Both UCP2 and UCP3 mRNA were
significantly increased at both time points as compared to 1 hour and 24 hour controls.
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AICAR effect on UCP3 mRNA in H9C2 cells
To further confirm this association, H9C2 cells were treated with AICAR for 1- or
24-hour periods, and mRNA expression was quantified by qRTPCR. After 1 hour
incubation with AICAR, a trend towards an increase in the expression of UCP2 on the
mRNA level was observed. In contrast, the expression of UCP3 mRNA was statistically
unchanged from control levels.

Figure 9. UCP mRNA expression in a cellular model after 1 hour AICAR treatment. H9C2 cells were
treated with 1 mM AICAR for 1 hour after which cells were harvested and mRNA isolated. qRTPCR
revealed a trend towards increased UCP2 mRNA with inconclusive UCP3 results. N=4.

After H9C2 cells were incubated with AICAR for 24-hours, a small but
statistically significant increase in UCP2 mRNA was observed, while UCP3 mRNA
levels remained unchanged compared to control levels.
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Figure 10. UCP mRNA expression in a cellular model after 24 hours of AICAR treatment. H9C2 cells were
treated with 1mM AICAR for 24 hours after which cells were harvested and mRNA isolated. qRTPCR
revealed a small but significant increase in UCP2 mRNA but no significant change in UCP3 mRNA. N=4.

AICAR effects on UCP protein expression in H9C2 Cells
Consistent with the mRNA results in the cellular model, immunoblots of UCP2
protein from H9C2 cells treated with AICAR demonstrated significantly increased UCP2
protein expression as compared to the controls samples after both one and twenty-four
hours of incubation with AICAR.

Figure 11. UCP2 protein expression in H9C2 cells after 1 hour of AICAR treatment. Western Blot
densitometric analysis demonstrated a significant increase of UCP2 protein in AICAR treated cells as
compared to controls. Data normalized to cytochrome c loading controls. N=5.
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Figure 12. UCP2 protein expression in H9C2 cells after 24 hours of AICAR treatment. Western blot
densitometric analysis demonstrated a small but statistically significant increase in UCP2 protein after
AMPK activation through AICAR treatment for 24 hours. Data normalized to cytochrome c loading
controls. N=6.

Treatment of H9C2 cells with AICAR for 1 hour did not result in an increase in
the level of UCP3 protein expression (data not pictured). In contrast, H9C2 incubation
with AICAR for 24 hours demonstrated a dramatic increase in UCP3 protein expression,
with the AICAR treatment resulting in UCP3 protein levels that were more than 15-fold
higher than control samples.

Figure 13. UCP3 protein expression in H9C2 cells after 24 hours of AICAR treatment. Western blot reveals
a dramatic increase in UCP3 protein in AICAR treated cells as compared to controls. Data normalized to
cytochrome c loading controls. N=6.
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AMPK activation and the UCP3 promoter
In the UCP3 promoter studies, a clear increase in firefly luciferase activity was
noted when H9C2 cells with the “middle” promoter construct were treated with AICAR
for one hour. In contrast, there was no increase in transcriptional activity in response to
AICAR for the “left” or “right” sections of the promoter. A large increase in luciferase
activity for the “long” construct with AICAR treatment was noted as well, though there
was a large degree of variation between measurements for this construct, and the
increased response of the “long” fragment, while impressive, remained statistically
insignificant.

Figure 14. Luciferase UCP3 promoter constructs response to AMPK activation with AICAR. Left panel
summarizes data from “fragment” UCP3 promoter constructs while right panel summarizes entire promoter
response, both compared to control. After 1 hour of incubation with 1mM AICAR, the entire promoter,
“Long,” demonstrates trend towards increased luminescence. The “middle” fragment construct has
significantly increased luminescence after AICAR treatment relative to control.
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DISCUSSION

These studies were performed to determine if AMPK activation results in an
increase in the expression of UCPs in the heart. We first demonstrated that the
pharmacologic activator, AICAR, increased AMPK phosphorylation in heart muscle both
after one hour and 24 hours of incubation. We then demonstrated that AMPK activation
was associated with increased expression of UCP2 and UCP3 mRNA at either 1 or 24
hours of stimulation with AICAR in adult mouse heart slices. In contrast, in H9C2
myocyte cultures, the changes in UCP mRNA were much less pronounced with only
UCP2 reaching statistical significance. However, we found little correlation between the
expression of the UCP mRNAs and expression of the UCPs on the protein level.
Specifically, there was only a small increase in UCP2 protein with AICAR incubation
while there was a dramatic 15-fold increase in the expression of UCP3 by 24 hours of
AMPK stimulation by AICAR. With respect to the regulation of UCP expression by
AMPK activation, we found that there is a region within the promoter region between 1600 and -697 bp upstream of the start codon that contains element(s) potentially
regulated by AMPK activation.

Table 3. Summary of UCP2 and UCP3 response to AICAR.

46

Using isolated mouse ventricle slices as a tissue model, we have demonstrated
that AMPK activation by AICAR leads to statistically significant increases in UCP2 and
UCP3 mRNA at both one-hour and twenty-four-hour time points. Interestingly, when
using a similar protocol in the H9C2 cellular model, UCP mRNA response was less
striking. UCP2 mRNA appeared to trend towards an increase at one hour and a small but
statistically significant increase was observed at twenty-four hours. No significant
difference in UCP3 mRNA was detected after either one hour or twenty-four hour
incubation with AICAR. This was particularly surprising given the robust response of
UCP3 at 24 hours in the mouse model.
These discrepant results might be explained by the fact that there is considerable
variation in UCP expression (and by extension, regulation) between different species and
even between different tissues within the same species. However, one would not expect
the observed UCP3 immunoblot results: while there was no difference between UCP3
protein levels in H9C2 mitochondrial isolations after one hour of AICAR incubation,
there was a striking increase in UCP3 protein in the cells incubated for 24 hours with
AICAR as compared to control samples. It is possible that there was a transient increase
in UCP3 mRNA at some time between one and twenty-four hours which had decayed by
the time points that were analyzed while the increase in protein expression remained
detectable. Alternatively, another potential explanation for the discrepancy between UCP
protein and mRNA results is suggested by the following previous studies. UCP2 protein
has been shown to increase up to 12-fold in mouse lung and stomach following
lipopolysaccharide treatment without any corresponding increase in UCP2 mRNA, a
result that these authors attributed to translational regulation.98 Such translational
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regulation may also contribute to determining UCP3 protein expression levels. In either
case, it was clear that 24-hour incubation of H9C2 cells with 1mM AICAR led to a
significant increase in UCP3 protein levels.
Given the evidence that AMPK activation regulates increased UCP expression in
skeletal muscle, and that this effect is likely mediated through modification of genetic
expression through AMPK translocation to the nucleus and/or AMPK-driven activation
of various transcription factors, we hypothesized that AMPK would employ a similar
mechanism in the heart. Specifically, AMPK activation was hypothesized to regulate
UCP2 and 3 expression by influencing cellular transcription. In constructing UCP3
promoter “fragments” we hoped to identify a region of the gene where activated AMPK
acts to induce increased expression of UCP3. Our results support the conclusion that such
a region exists somewhere between -1600 and -697 base pairs upstream of the
transcription start site. Further characterization of this site and the possible mechanism of
interaction remain to be investigated.
Limitations
A limit to our study includes the incomplete identification of the UCP3 promoter
site referenced above, as well as a lack of in vivo data to support our experimental
models. Given the cross-species variation of UCP expression, it is also not unreasonable
to question whether data from mouse and rat models can be generalized to humans.
Although most data concerning UCP expression and function in the heart thus far support
a system relatively conserved across these species, further investigation in humans is
warranted.
Similarly, although recent research has indicated that UCP3 protein is present in
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the adult heart, while there remains a considerable degree of controversy as to whether
UCP2 protein is expressed in cardiomyocyte mitochondria.97 Our decision to investigate
the UCP3 promoter, and not UCP2, was influenced by this uncertainty. Nevertheless, our
findings of UCP2 protein in H9c2 preparations support the conclusion that UCP2 may, in
fact, be expressed in the myocardium.
Yet our choice of cellular model may also be interpreted as a limitation. The
H9C2 cell line was derived from fetal rat cardiomyocytes to allow for multiplication in
culture.95 Adult cardiomyocytes are terminally differentiated and must be repeatedly
obtained from sacrificed animals. This is labor-intensive and difficult. While
advantageous in this respect, H9C2 cells are not ideal in that they do not completely
retain the characteristics of isolated (or in vivo) adult cardiomyocytes. For example,
H9C2 cells lack the gap junctions, caveolae, T tubules, and microfibriller sarcomeres of
freshly prepared cardiomyocytes. Nevertheless, the composition of the surface coat as
well as many of the ion channels and signaling proteins remain similar or identical
between the immortalized H9C2 cell line and the isolated cardiomyocte.99 Further studies
employing an isolated cardiomyocyte model, while laborious, would strengthen the
observations made in this study.
A further minor limitation of our study is our method of verifying AMPK
activation. In addition to pAMPK immunoblotting, we could have checked downstream
ACC activation or performed AMPK activity assays to prove AMPK activation.
However, given the general agreement that phosphorylation is indicative of activation,
we felt that such measures would be superfluous.
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It should be noted, however, that AICAR is a relatively nonspecific activator of
AMPK and, as such, upregulation of the UCPs upon AICAR treatment does not
specifically prove a cause and effect relationship between AMPK activation and
increased UCP expression, although it does strongly support such a conclusion.94 To
remove any doubt that activated AMPK causes UCP upregulation, further experiments
could be conducted treating an AMPK deficient model (AMPK KD cardiomyocytes or
H9C2 cells transfected with an AMPK KD vector) with AICAR in an attempt to observe
a lack of UCP response.
Clinical Support
Despite the limitations of our study, previous data support our conclusions. The
chemical activator of AMPK, AICAR, has previously been used in clinical trials as a
cardioprotective agent (although this was not done specifically to upregulate UCPs, or
even to phosphorylate AMPK). A meta-analysis of studies employing acadasine (the
formulary name for AICAR) to treat patients before and after coronary artery bypass
graft surgery demonstrated that treatment with the drug yielded moderate benefits.
Specifically, acadesine decreased the need for left ventricular assist devices, the number
of peri-operative myocardial infarctions, and the number of post-operative cardiac deaths
when compared to placebo treatment.100 Acadasine was developed as an adenosine
reuptake inhibitor to promote activation of adenosine receptors in the ischemic heart and
to potentially help replenish depleted myocardial stores of GTP and ATP.69 The drug was
ultimately abandoned because it only weakly augmented the adenosine pathway. The
relatively modest effects could be explained by the fact that AICAR is only a weak
activator of AMPK.70, 94 Furthermore, AICAR is not an ideal activator because it must be
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converted to ZMP through phosphorylation to exert its effects, and has significant side
effects including bradycardia and hypoglycemia.68
At the time the clinical studies using AICAR were conducted, the actions of this
chemical were incompletely understood. Neither activation of AMPK nor upregulation of
the UCPs was considered as a potentially cardioprotective mechanism. Nevertheless, the
moderately successful results of this drug may be explained by this pathway, and provide
important human, clinical evidence that AICAR activation of AMPK (and potential
upregulation of cardiac UCPs) improves outcomes after exposure to hypoxia/ischemia.
Future Directions
UCPs have many important potential clinical benefits including protection of the
heart during periods of ischemia and reperfusion, as well as a role in the prevention of
heart failure. Our results support the idea that AMPK activation induces UCP
upregulation through a mechanism involving interaction with the UCP promoter.
However, some pieces of the puzzle remain missing. For example, we do not yet have
data as to the promoter response after 24 hours of AICAR incubation, though we expect
that the “Middle” fragment will yield increased luciferase activity as was observed in the
1 hour incubations. Further experiments will cull the size of the promoter fragments until
we have isolated the nucleotide sequence that appears to be responsible for the AMPKinduced upregulation of UCP3. We also hope to identify potential transcription factors
that might interact with this region. Finally, we will confirm the involvement of AMPK
in the upregulation of the UCPs through the use of AMPK KO mouse models or AMPK
deficient cell lines (as mentioned above). We believe that future studies of the role of
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AICAR in UCP regulation utilizing in vivo animal models and human subjects will
clarify this important pathway and may lead to novel cardioprotective therapies.

52
CONCLUSIONS

We hypothesized that one of the pathways responsible for increased expression of
cardiac uncoupling proteins involves activation of AMP-activated protein kinase. Our
data show that pharmacologic AMPK activation with the AMP-mimetic, AICAR, leads
to increased levels of UCP2 and UCP3 mRNA in an isolated tissue model. We have
further shown that UCP2 and UCP3 protein expression in a cellular cardiomyocyte model
is increased as a result of AICAR treatment. Finally, we have identified a 1000 base pair
region of the UCP3 promoter which appears to mediate AMPK-activated UCP
transcriptional upregulation. Taken together, these data support the idea that activation of
AMPK is a critical step in increasing myocardial expression of the mitochondrial
uncoupling proteins.
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